Needham & Company LLC Reaffirms “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Needham & Company LLC reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report issued on Tuesday,Benzinga reports. Needham & Company LLC currently has a $6.00 price objective on the stock.

Several other equities analysts also recently commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Canaccord Genuity Group decreased their price target on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $2.06 on Tuesday. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $422.18 million, a P/E ratio of 3.27 and a beta of 0.44. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The stock has a 50 day moving average of $1.98 and a 200-day moving average of $2.38.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TSHA. Creative Planning acquired a new stake in Taysha Gene Therapies during the third quarter worth approximately $28,000. Principal Financial Group Inc. acquired a new position in Taysha Gene Therapies in the second quarter valued at about $48,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after acquiring an additional 17,446 shares during the period. Intech Investment Management LLC acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth $85,000. Finally, Scientech Research LLC bought a new position in shares of Taysha Gene Therapies in the second quarter worth about $97,000. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.